ライフサイエンスコーパス: gastrojejunostomy

1 as a significant risk in 107 and performed a gastrojejunostomy.

2 phylactic retrocolic gastrojejunostomy or no gastrojejunostomy.

3 stoperative morbidity rates were comparable (gastrojejunostomy 32%, no gastrojejunostomy 33%).

4 s were comparable (gastrojejunostomy 32%, no gastrojejunostomy 33%).

5 veloped, requiring therapeutic intervention (gastrojejunostomy 7 patients, endoscopic duodenal stent

6 ing revisions, were performed, including 643 gastrojejunostomies (92%) and 58 gastrostomies (8.3%).

7 erwent a subtotal gastrectomy with Roux-en-Y gastrojejunostomy along with D2 nodal dissection.

8 ndomized, 44 patients underwent a retrocolic gastrojejunostomy and 43 did not undergo a gastric bypas

9 The gastrojejunostomy and jejunojejunostomy were primarily c

10 nctional duration of percutaneous endoscopic gastrojejunostomy and reported outcomes of direct percut

11 ortant to appreciate the patency of both the gastrojejunostomy and the jejunojejunostomy, as well as

12 age, gender, procedure performed (excluding gastrojejunostomy), and surgical findings.

13 The performance of a prophylactic retrocolic gastrojejunostomy at the initial surgical procedure does

14 Placement of a 14-F gastrostomy or gastrojejunostomy catheter was then accomplished with th

15 ed percutaneous placement of gastrostomy and gastrojejunostomy catheters with routine gastropexy is a

16 trointestinal surgical procedures, including gastrojejunostomy, cholecystectomy, splenectomy, and dis

17 late gastric outlet obstruction, requiring a gastrojejunostomy, develops in 10% to 20% of patients wi

18 pically directed percutaneous gastrostomy or gastrojejunostomy during a 9 1/2-year period.

19 er drainage (EUS-GBD), endoscopic ultrasound gastrojejunostomy (EUS-GJ).

20 partially attributable to dilatation of the gastrojejunostomy (GJ), which diminishes the restrictive

21 ve length of stay was 8.5+/-0.5 days for the gastrojejunostomy group and 8.0+/-0.5 days for the no ga

22 unostomy group and 8.0+/-0.5 days for the no gastrojejunostomy group.

23 esigned to evaluate the role of prophylactic gastrojejunostomy in patients found at exploratory lapar

24 to assess modified retro colic retro gastric gastrojejunostomy in reducing macro and microscopic bile

25 aditional use of enteral stents and surgical gastrojejunostomy in the management of malignant GOO.

26 n six patients, anastomotic leakage from the gastrojejunostomy line in two patients, superior mesente

27 s were treated with subtotal gastrectomy and gastrojejunostomy (n = 5) or total gastrectomy and esoph

28 to receive either a prophylactic retrocolic gastrojejunostomy or no gastrojejunostomy.

29 ated patients who underwent the percutaneous gastrojejunostomy procedure.

30 Whether or not to perform a prophylactic gastrojejunostomy remains unresolved.

31 A retrocolic gastrojejunostomy should be performed routinely when a p

32 ndomized trial demonstrate that prophylactic gastrojejunostomy significantly decreases the incidence

33 pT4 signet-ring cell carcinoma involving the gastrojejunostomy site that was revealed by bleeding or

34 ants had jejunal placement of a percutaneous gastrojejunostomy tube, and were then randomly allocated

35 us), mainly associated with the percutaneous gastrojejunostomy tube.

36 ival among those who received a prophylactic gastrojejunostomy was 8.3 months, and during that interv

37 among those who did not have a prophylactic gastrojejunostomy was 8.3 months.

38 a fully endoscopic controlled bypass length gastrojejunostomy with duodenal exclusion in a growing p

39 secutive patients, radiologic gastrostomy or gastrojejunostomy with T-fastener gastropexy was perform